Market Overview

Morgan Stanley Updates Estimates On Endo Health Solutions

Related ENDP
Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain
US Stock Futures Up Ahead Of Economic Data

In a report published Monday, Morgan Stanley analyst Christopher Caponetti reiterated an Equal-Weight rating on Endo Health Solutions (NASDAQ: ENDP).

In the report, Morgan Stanley noted, “Endo's 1.75% convertible notes (due March 2015) and warrants are in-the-money and add roughly 13-15M to Endo's fully-diluted share count. Our new 2014E EPS est. of $3.61 is down 11% vs. our previous $4.05 and near the high end of mgmt's $3.41-$3.65 range (midpt $3.53). Key assumptions: 1. Mylan launches generic Lidoderm in mid-2Q ($49M in royalties from ACT); 2. no generic competition on Voltaren Gel in 2014; 3. 21.6% tax rate; 4. opex down 12% YOY. Delay of Mylan's launch of Gx Lidoderm, more aggressive cost cutting, and lower tax rate are sources of near-term EPS upside.”

Endo Health Solutions closed on Friday at $79.82.

Latest Ratings for ENDP

DateFirmActionFromTo
Oct 2014Guggenheim SecuritiesInitiates Coverage onBuy
Oct 2014Cantor FitzgeraldUpgradesSellHold
Sep 2014RBC CapitalInitiates Coverage onOutperform

View More Analyst Ratings for ENDP
View the Latest Analyst Ratings

Posted-In: Christopher Caponetti Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (ENDP)

Around the Web, We're Loving...

Get Benzinga's Newsletters